Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
31
ADVM Quote, Financials, Valuation and Earnings
Last price:
$4.18
Seasonality move
:
-11.49%
Day range:
$4.16 - $4.19
52-week range:
$1.78 - $6.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
89.16x
P/B ratio:
1.95x
Volume:
464.3K
Avg. volume:
856.7K
1-year change:
-34.12%
Market cap:
$92.1M
Revenue:
$1M
EPS (TTM):
-$8.57
Analysts' Opinion
-
Consensus RatingAdverum Biotechnologies, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.90, Adverum Biotechnologies, Inc. has an estimated upside of 17.51% from its current price of $4.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $4.17.
Fair Value
-
According to the consensus of 6 analysts, Adverum Biotechnologies, Inc. has 17.51% upside to fair value with a price target of $4.90 per share.
ADVM vs. S&P 500
-
Over the past 5 trading days, Adverum Biotechnologies, Inc. has overperformed the S&P 500 by 1.95% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Adverum Biotechnologies, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Adverum Biotechnologies, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Adverum Biotechnologies, Inc. reported revenues of --.
Earnings Growth
-
Adverum Biotechnologies, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Adverum Biotechnologies, Inc. reported earnings per share of -$2.03.
Enterprise value:
154.9M
EV / Invested capital:
4.65x
Price / LTM sales:
89.16x
EV / EBIT:
--
EV / Revenue:
141.54x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-1.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2.5M
Return On Assets:
-128.25%
Net Income Margin (TTM):
-16427.5%
Return On Equity:
-558.69%
Return On Invested Capital:
-152.8%
Operating Margin:
-2922.1%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.6M | $1M | -- | $1M | -- | |
| Gross Profit | -$9.7M | -$2.9M | -$2.5M | $110K | -$465K | |
| Operating Income | -$131.8M | -$115M | -$190.7M | -$25.9M | -$47M | |
| EBITDA | -$118.5M | -$111.1M | -$188.2M | -$25M | -$46.6M | |
| Diluted EPS | -$12.56 | -$7.08 | -$8.57 | -$1.55 | -$2.03 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $347.8M | $213.2M | $124.6M | $161.1M | $28.9M | |
| Total Assets | $490.6M | $332.4M | $196.8M | $234.4M | $72.4M | |
| Current Liabilities | $25.3M | $28.6M | $28.9M | $27.7M | $44.7M | |
| Total Liabilities | $144.6M | $124M | $94.1M | $90.3M | $128.1M | |
| Total Equity | $346M | $208.3M | $102.7M | $144.1M | -$55.7M | |
| Total Debt | $122.4M | $94.5M | $65.2M | $62.6M | $83.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$88.4M | -$85.6M | -$137.9M | -$21.1M | -$28.1M | |
| Cash From Investing | $109M | -$47.6M | $60.9M | -$13.3M | $1.9M | |
| Cash From Financing | $489K | $120M | $10.3M | -- | $9.9M | |
| Free Cash Flow | -$89.2M | -$86.1M | -$138.4M | -$21.3M | -$28.3M | |
ADVM
Sector
Market Cap
$92.1M
$28.4M
Price % of 52-Week High
64.65%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-13.31%
-1.32%
1-Year Price Total Return
-34.12%
-22.19%
Beta (5-Year)
0.869
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.15
200-day SMA
Buy
Level
$3.47
Bollinger Bands (100)
Buy
Level
2.8 - 4.5
Chaikin Money Flow
Sell
Level
-29.7M
20-day SMA
Sell
Level
$4.22
Relative Strength Index (RSI14)
Sell
Level
46.94
ADX Line
Sell
Level
15.32
Williams %R
Neutral
Level
-45.6482
50-day SMA
Sell
Level
$4.42
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Sell
Level
-13.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.8521)
Sell
CA Score
(Annual)
Level (-4.9868)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.1046)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
Stock Forecast FAQ
In the current month, ADVM has received 2 Buy ratings 4 Hold ratings, and 0 Sell ratings. The ADVM average analyst price target in the past 3 months is $4.90.
-
Where Will Adverum Biotechnologies, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Adverum Biotechnologies, Inc. share price will rise to $4.90 per share over the next 12 months.
-
What Do Analysts Say About Adverum Biotechnologies, Inc.?
Analysts are divided on their view about Adverum Biotechnologies, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Adverum Biotechnologies, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Adverum Biotechnologies, Inc.'s Price Target?
The price target for Adverum Biotechnologies, Inc. over the next 1-year time period is forecast to be $4.90 according to 6 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is ADVM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Adverum Biotechnologies, Inc. is a Hold. 4 of 6 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ADVM?
You can purchase shares of Adverum Biotechnologies, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Adverum Biotechnologies, Inc. shares.
-
What Is The Adverum Biotechnologies, Inc. Share Price Today?
Adverum Biotechnologies, Inc. was last trading at $4.18 per share. This represents the most recent stock quote for Adverum Biotechnologies, Inc.. Yesterday, Adverum Biotechnologies, Inc. closed at $4.17 per share.
-
How To Buy Adverum Biotechnologies, Inc. Stock Online?
In order to purchase Adverum Biotechnologies, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ADVM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ADVM
Sector
P/E ratio
--
23.66x
PEG ratio
-0.02x
-0.01x
P/B ratio
1.95x
1.84x
Price / LTM sales
89.16x
1.60x
Growth Metrics
ADVM
Sector
Revenue growth
-100%
4.85%
Earnings growth
-30.92%
11.15%
Revenue (5-year growth)
31.95%
6.45%
Earnings forecast
-$1.68
-$0.20
Profitability
ADVM
Sector
Profitability FY 2024
-$2.7M
$3.6M
Return on invested capital
-152.8%
-30.98%
Return on assets
-128.25%
-27.62%
Return on equity
-558.69%
-36.69%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
13
Balance Sheet
ADVM
Sector
Total cash
$26.1M
$27.2M
Short term investments
$65M
$25.7M
Total assets
$179.8M
$79.9M
Long term debt
$83.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
